Marksans Pharma Ltd
Next 500 2024
+ 8 More
+ 8 More
Share
Share
OVERVIEW
FINANCIALS
About
Marksans Pharma is an Indian pharmaceutical company specialising in over-the-counter (OTC) and prescription drugs. Applications of these drugs range from pain management, antibiotics, and cough and cold to antidiabetics, oncology, and digestives. Its manufacturing facilities in North Goa, Verna, Farmingdale, US, and Southport, UK, have been approved by regulatory agencies the Food and Drugs Administration (FDA) of the US and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK. These facilities help in producing over 300 different kinds of products for over 50 markets all around the world. Marksans Pharma is one of the top 5 Indian companies in the United Kingdom.
Incorporation Year: 1992
Headquarters: Mumbai
Top Management: Mark Saldanha
Industry: Pharma
Website: www.marksanspharma.com
Featured In Fortune India Ranking
Next 500 India
#276(2024)#239(2023)#95(2022)#224(2021)#298(2020)#301(2019)#377(2018)#339(2017)#347(2016)
#276(2024)#239(2023)#95(2022)#224(2021)#298(2020)#301(2019)#377(2018)#339(2017)#347(2016)
Ranking Trend Fortune Next 500 India
Financial Data 2024
Revenue
2,302
(INR Cr)
Net Operating Income
2,177
(INR Cr)
Assets
2,335
(INR Cr)
Profit
314
(INR Cr)
Net Worth
2,065
(INR Cr)
Financial Data
RevenueNet Operating IncomeProfitAssetsNet Worth
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 2302 20.0% | 1918 26.2% | 1520 0.0% | 1519 40.5% | 1082 5.6% | 1025 13.8% | 901 9.6% | 822 -8.4% | 897 12.0% | 801 25.9% | 636 47.7% | 431 24.5% | 346 12.7% | 307 -11.2% | 345 -7.4% | 373 - |
| Net Operating Income (INR Cr) | 2177 17.56% | 1852 24.23% | 1491 8.33% | 1376 21.33% | 1134 13.41% | 1000 9.57% | 913 18.97% | 767 -14.12% | 893 12.13% | 797 26.46% | 630 43.70% | 438 23.31% | 356 16.73% | 305 -15.25% | 359 0.92% | 356 38.33% |
| Profit (INR Cr) | 314 17.8% | 266 44.3% | 185 -21.8% | 236 95.4% | 121 57.9% | 76 132.1% | 33 272.6% | 9 -88.7% | 79 -28.2% | 109 52.1% | 72 56.7% | 46 - | -179 - | -223 - | -10 - | -8 - |
| Assets (INR Cr) | 2335 23.4% | 1891 41.6% | 1336 41.1% | 947 38.1% | 685 3.2% | 664 9.0% | 609 8.6% | 561 2.0% | 551 15.6% | 476 54.4% | 309 20.4% | 256 1469.4% | 16 -77.4% | 72 -87.7% | 586 7.0% | 548 - |
| Net Worth (INR Cr) | 2065 18.3% | 1745 45.2% | 1202 35.6% | 886 39.4% | 636 17.2% | 542 15.2% | 471 8.6% | 433 -1.9% | 442 20.3% | 367 185.4% | 129 76.3% | 73 140.2% | -182 -131.0% | -79 -153.3% | 148 7.9% | 137 6.6% |
| Employee Cost (INR Cr) | 294 22.7% | 239 8.7% | 220 11.7% | 197 17.2% | 168 5.9% | 159 7.7% | 148 -1.3% | 150 22.3% | 122 68.6% | 73 9.3% | 66 18.8% | 56 22.3% | 46 26.0% | 36 2.5% | 35 -3.8% | 37 - |
| Interest Cost (INR Cr) | 11 | 9 | 8 | 8 | 9 | 10 | 10 | 7 | 10 | 16 | 19 | 15 | 54 | 44 | 19 | 21 |
| Cash & Bank Balance (INR Cr) | 674 | 715 | 349 | 212 | 94 | 34 | 40 | 25 | 35 | 185 | 47 | 16 | 22 | 31 | 36 | 22 |
| Total Debt (INR Cr) | 244 | 123 | 111 | 34 | 30 | 100 | 118 | 110 | 88 | 89 | 160 | 163 | 179 | 135 | 424 | 397 |
Key Financial Ratios
Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 13.6% | 13.9% | 12.1% | 15.5% | 11.2% | 7.5% | 3.7% | 1.1% | 8.8% | 13.7% | 11.3% | 10.7% | - | - | - | - |
| Profit As % Of Assets | 13.4% | 14.1% | 13.8% | 24.9% | 17.6% | 11.5% | 5.4% | 1.6% | 14.3% | 23.0% | 23.3% | 17.9% | - | - | - | - |
| Profit As % Of Networth | 15.2% | 15.3% | 15.4% | 26.6% | 19.0% | 14.1% | 7.0% | 2.0% | 17.8% | 29.8% | 55.9% | 62.9% | - | - | - | - |
| Interest Cost to EBITDA % | 2.4% | 2.7% | 3.3% | 2.4% | 4.6% | 7.3% | 13.0% | 15.2% | 7.5% | 8.7% | 16.3% | 21.0% | - | - | 81.3% | 98.7% |
| Debt to Equity Ratio | 0.12 | 0.07 | 0.09 | 0.04 | 0.05 | 0.18 | 0.25 | 0.25 | 0.20 | 0.24 | 1.24 | 2.23 | - | - | 2.87 | 2.90 |
| RONW | 16.5% | 18.0% | 17.9% | 31.3% | 20.5% | 14.9% | 6.7% | 2.1% | 15.7% | 24.8% | 19.1% | 46.0% | - | - | - | - |
| ROCE | 20.8% | 21.8% | 22.8% | 38.8% | 25.0% | 17.2% | 9.1% | 3.4% | 18.6% | 29.2% | 18.8% | 20.0% | 0.0% | 0.0% | 1.8% | 2.8% |